Effects of GCP on Prostate Cancer.

University of California, Davis62 enrolled

Overview

Genistein Combined Polysaccharide (GCP) is derived from adding soy powder to shiitake mushrooms. This concentrated mixture is currently being sold in Japan and the United States and is thought to possibly contain properties that may be useful in treating certain types of cancer.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Prostate Cancer

Interventions

Genistein Combined Polysaccharide (GCP)DRUG

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: Participants must be male and have a pathological diagnosis of prostate cancer. No treatment (surgery \[RRP\], radiation, or hormones) prior to study entry. The patient has decided, after consultation with his own doctor, to have no treatment intervention (surgery \[RRP\], radiation, or hormones) for the next six months. PSA between 2.0 and 10.0 ng/ml. If PSA is \>10.0, patient must have been on Active Surveillance for 12 months prior to study initiation. No known allergy to soy or soy products. The patient is not currently taking more than 2 grams of genistein a day in nutritional or diet enhancing supplements (OTC supplements). \- Exclusion Criteria: No pathological documentation of prostate cancer. Allergy to soy or soy products Prior history of treatment for prostate cancer. \-

Locations (1)

University of California, Davis

Sacramento, California, United States

Outcomes

Primary Outcomes

Reduction in PSA serum levels.

Secondary Outcomes

Stabilization of PSA serum levels.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.